within Pharmacolibrary.Drugs.ATC.N;

model N02CA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.025,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.036,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Dihydroergotamine is an ergot alkaloid medication primarily used for the treatment of migraine headaches and cluster headaches. It acts as a vasoconstrictor of intracranial arteries, and as an agonist at serotonin (5-HT1) receptors. It is approved and still in use for acute migraine attacks by several regulatory agencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><a href='https://dx.doi.org/10.1111/j.1365-2125.1989.tb03427.x'>10.1111/j.1365-2125.1989.tb03427.x</a> Parameters were extracted from published pharmacokinetic studies in healthy volunteers using two-compartment models after IV administration (e.g., Lataste H, et al. 1989).</li></ol></body></html>",
    revisions = "<html><body><ul><li>03/06/2025 model generated from PK parameters and knowledge obtained by LLM gpt-4.1 and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02CA01;
